Novo Nordisk A/S announced a share repurchase program of up to DKK 20 billion starting from February 6, 2024, and has repurchased 394,500 B shares for DKK 327,673,060 at an average price of DKK 830.60 as of February 16, 2024. This is part of the company’s strategy to manage its capital structure and enhance shareholder value.